Results
|
|
1.
|
|
|
|
2.
|
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study. MedStar authors:
Year: 2021
Citation: - Leukemia & Lymphoma. 62(8):1816-1827, 2021 08.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ahn IE, Desai S, Drinkwater DC, Farooqui MZ, Gaglione EM, Herman SEM, Hughes TE, Lindorfer MA, Lotter J, Maric I, Marti GE, Mo C, Nichols C, Nierman P, Pleyer C, Soto S, Stetler-Stevenson M, Sun C, Superata J, Taylor RP, Tian X, Valdez J, Wake L, Wiestner A, Yuan CM
|
|
|
3.
|
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. MedStar authors:
Year: 2017
Citation: - Annals of Oncology. 28(5):1050-1056, 2017 May 01
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Barr PM, Brander DM, Cheson BD, Claxton DF, Cruz AL, Daniel C, Fanning M, Foon K, Gashonia L, Goy A, Henick Bachow S, Hill BT, Howlett C, Isaac K, Kennard KH, Kiselev P, Lamanna N, Lenhart J, Mato AR, Nabhan C, Pu JJ, Schuster SJ, Skarbnik AP, Svoboda J, Timlin C, Ujjani CS, Winter AM, Yacur M, Zent CS
|
|
|
4.
|
|
